Paul A. Mahon - 05 Mar 2026 Form 4 Insider Report for UNITED THERAPEUTICS Corp (UTHR)

Role
EVP & GENERAL COUNSEL
Signature
/s/ John S. Hess, Jr. under Power of Attorney
Issuer symbol
UTHR
Transactions as of
05 Mar 2026
Net transactions value
-$4,010,187
Form type
4
Filing time
05 Mar 2026, 16:37:26 UTC
Previous filing
19 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
MAHON PAUL A EVP & GENERAL COUNSEL C/O UNITED THERAPEUTICS CORPORATION, 1000 SPRING STREET, SILVER SPRING /s/ John S. Hess, Jr. under Power of Attorney 05 Mar 2026 0001231589

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction UTHR Common Stock Options Exercise +8,300 +23% $146.03* 45,144 05 Mar 2026 Direct F1, F2
transaction UTHR Common Stock Sale $176,429 -368 -0.82% $479.43 44,776 05 Mar 2026 Direct F1, F3
transaction UTHR Common Stock Sale $769,310 -1,602 -3.6% $480.22 43,174 05 Mar 2026 Direct F1, F4
transaction UTHR Common Stock Sale $346,559 -720 -1.7% $481.33 42,454 05 Mar 2026 Direct F1, F5
transaction UTHR Common Stock Sale $568,114 -1,177 -2.8% $482.68 41,277 05 Mar 2026 Direct F1, F6
transaction UTHR Common Stock Sale $525,123 -1,086 -2.6% $483.54 40,191 05 Mar 2026 Direct F1, F7
transaction UTHR Common Stock Sale $677,403 -1,398 -3.5% $484.55 38,793 05 Mar 2026 Direct F1, F8
transaction UTHR Common Stock Sale $488,236 -1,006 -2.6% $485.32 37,787 05 Mar 2026 Direct F1, F9
transaction UTHR Common Stock Sale $361,482 -743 -2% $486.52 37,044 05 Mar 2026 Direct F1, F10
transaction UTHR Common Stock Sale $97,530 -200 -0.54% $487.65 36,844 05 Mar 2026 Direct F1, F11

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction UTHR Stock Option Options Exercise -8,300 -20% $0.000000* 33,500 05 Mar 2026 Common Stock 8,300 $146.03 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
F10 This transaction was executed in multiple trades at prices ranging from $486.41 to $486.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F11 This transaction was executed in multiple trades at prices ranging from $487.475 to $487.77. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 Includes 63 shares of common stock acquired on March 4, 2026 under the United Therapeutics Employee Stock Purchase Plan.
F3 This transaction was executed in multiple trades at prices ranging from $478.82 to $479.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 This transaction was executed in multiple trades at prices ranging from $479.82 to $480.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5 This transaction was executed in multiple trades at prices ranging from $481.02 to $481.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6 This transaction was executed in multiple trades at prices ranging from $482.025 to $482.86. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7 This transaction was executed in multiple trades at prices ranging from $483.07 to $484.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8 This transaction was executed in multiple trades at prices ranging from $484.07 to $484.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F9 This transaction was executed in multiple trades at prices ranging from $485.10 to $485.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.